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Are fine-needle breast aspirates representative of the underlying solid
tumour? A comparison of receptor levels, ploidy and the influence of
cytokeratin gates
I Brotherick, BK Shenton and TWJ Lennard
Department ofSurgerY, Medical School, University of.Vewcastle upon Tyne, UK.
Summary- Fifty-three solid and 33 fine-needle aspirate (FNA) samples (20 paired) of human breast car-
cinomas were examined by flow cytometry. Experiments were conducted to assess whether FNA samples were
phenotypically representative of the solid tumour. Quantification of oestrogen receptor (ER), epidermal
growth factor receptor (EGFR). c-erbB-2 receptor levels and ploidy were examined on the total and
cytokeratin-positive cell populations. The absolute number of molecules of cytokeratin per cell expressed on
the FNA (n = 33) and solid tumour (n = 53) samples showed no significant difference, but, on a proportional
basis. there was a significant difference between the two samples (P = 0.004). with lower expression exhibited
by the FNAs. Examination of paired data showed no significant difference in the percentage of cytokeratin-
positive cells (P = 0.51) or in the number of cytokeratin molecules expressed (P = 0.25). While the correlation
for ER expression between paired tumour and FNA samples in the absence of cytokeratin gating was
P = 0.06. r = 0.18. clear correlation was shown when a cytokeratin gate was used (P=0.005. r = 0.4).
Repeating this experiment for EGFR. it was found that no correlation was seen between FNA and solid
tumour (P= 0.2. r = 0.14) in ungated populations. but use of the cytokeratin gate improved the correlation
(P= 0.05. r = 0.3). A similar finding was seen with c-erbB-2 expression (P = 0.2. r = 0.1) without cytokeratin
gating and when it was employed (P= 0.05. r = 0.4). Ploidy data showed concordance in 18/20 cases. Three
cases of aneuploidy were missed by FNA. and this was because of an insufficient number of cells for analysis.
The presented data suggest that FNAs are representative of solid tumours and may be useful for measuring
receptor levels on clinical material when cytokeratin gating is used. However, observation by light microscopy
is still necessary to confirm the presence of tumour cells in FNAs subjected to flow cytometry.
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Fine-needle aspiration of breast tumours is being used
increasingly as a diagnostic modality. For a high level of
diagnostic accuracy both aspirator and cytologist must be
highly experienced (Brown et al., 1991; Powles et al., 1991).
Little has been done to assess potentially important prognos-
tic markers within such samples using flow cytometry.
Immunohistochemical studies of breast tumours are usually
restricted to frozen or paraffin-embedded sections of post-
operative tissue. and solid tumour sampling usually occurs
after surgery. Flow cytometric studies of these tumours are
therefore reliant on rapid processing by the histopathologist.
Of more significance, information obtained from the tumour
is only available after surgery and treatment has occurred.
FNA sampling allows a 'preview' of cancers and, if suitable
prognostic markers are examined, could potentially influence
treatment. A further reason for using FNAs is the fact that
tumours are being detected at an early stage, are small and
the quantity of material available may be limited. The ability
to examine FNAs at this early stage may offer potential
benefits to both the surgeon and the pathologist.
It has been reported that examination of solid tumours for
epidermal growth factor receptor (EGFR; Nicholson et al.,
1988; Sainsbury et al., 1985), oestrogen receptor (ER; Howell
et al., 1984), c-erbB-2 (Berger et al., 1988; Paik et al., 1990;
Gullick et al., 1991; Perren, 1991) and DNA (Yuan et al.,
1991) are of prognostic use and can be assessed by flow
cytometry. Both ER and EGFR, measured by flow
cytometry, have been shown to compare well with conven-
tional radioligand binding assays (Brockhof et al.. 1994:
Brotherick et al.. 1994a, 1995).
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Positive oestrogen receptor status has been shown to be
linked to node-negative disease, indicating superior prog-
nosis, and predicts for a lower histological grade (Howell et
al., 1984). Overexpression of c-erbB-2 has been shown to be
linked with poor prognosis (Wright et al., 1989; Perren,
1991), shorter relapse-free survival, adverse nodal status
(Slamon et al., 1987; Gullick et al., 1991) and poor his-
tological grade (Berger et al., 1988). The presence of EGFR
has been identified as a marker of poor prognosis, showing a
positive correlation with tumour grade (Sainsbury et al.,
1985). Ploidy has been linked to prognostic survival in node-
negative breast cancer (Yuan et al.. 1991). Prediction of node
status and tumour grade before tumour removal is thus a
valuable indicator of patient outcome and could influence
patient treatment. Indeed, if tumour FNA measurements
using flow cytometry can be shown to be of prognostic value
they may allow treatment protocol design for each individual
patient and her tumour.
The use of prognostic markers, FNA and flow cytometry is
still at an early stage. Examination of large numbers of
tumour cells by flow cytometry still presents a number of
potential problems. Tumours are a very heterogeneous
population of cells with normal epithelium, stromal cells, red
blood cells and immune cell infiltrates constituting some of
the mass of tissue removed (Whiteside et al., 1986).
Cytokeratin gating has been shown to be of some use in
removing non-epithelial cell 'noise' from data obtained by
flow cytometry (Ferrero et al., 1990). This has enabled the
detection of weakly expressed antigens such as ER
(Brothenrck et al., 1995). However, FNAs contain fewer cells
than a solid tumour sample and thus 'contaminating' cells
assume much more importance.
This paper seeks to examine the efficacy of cytokeratin
gating in both solid tumours and FNAs of malignant breast
cancers and the effect of such gating on the expression of
oestrogen receptor, c-erbB-2 and epidermal growth factor
receptor.Materak an methods
Patients and specinens
Patients with confirmed malignant breast disease diagnosed
by fine-needle aspiration cytology were recruited for this
study. The presence of tumour cells being confirmed by this
methodology. After general anaesthesia, but before surgery
(wide excision/mastectomy), multiple fine-needle aspirates of
breast tumour were taken.
All fine-needle aspirate sampling was performed by the
same consultant surgeon. Aspiration was performed using a
21 gauge needle (Terumo Europe, Leuven, Belgium) and
20 ml syringe (Terumo). The needle was passed into the
palpable lump, suction applied and the needle passed in four
directions backwards and forwards 12-15 times through the
lump to attain adequate sample according to an agreed
protocol (informed consent was obtained and the protocol
received ethical approval). The needle was then removed and
the cellular material washed out of the needle using Isoton II
(Coulter Electronics, Luton, Bedfordshire, UK) and a 5 ml
syringe (Terumo). The specimen was processed as soon as
possible to cut down degradation/congealing of the sample.
Multiple samples from each patient were pooled and used
directly or frozen at - 70C in 10% dimethylsulphoxide
(DMSO) (Sigma, Poole, Dorset, UK). The sample was
washed in Isoton II (Coulter) with vigorous mixing and
centrifuged at 400 g for 10 min. Depending on the size of the
cell pellet the material was resuspended in between 400 and
600 11 of Isoton II (Coulter) before preparation for flow
cytometry.
Solid tumour samples were collected post-operatively.
Limitations to tumour collection were mainly at the
pathologist's discretion: no sample was taken if insufficient
tumour material would be left for routine histological
examination, clearance margins were not distinguishable or if
the tumour was in small diffuse populations.
Mastectomy/wide excision specimens were rapidly trans-
ported to the Department of Pathology (Royal Victoria
Infirmary, Newcastle upon Tyne, UK) and immediately pro-
cessed. Samples were taken from visibly identified areas of
tumour and were usually cubes with sides of between 2 and
8 mm. Solid tumour samples were either stored in liquid
nitrogen or processed immediately. The tumour was finely
minced in Isoton II (Coulter) and passed through a fine wire
mesh (-50 pm). The resulting cell suspension was cent-
rifuged at 400 g for 10min and resuspended in Isoton II
(Coulter) at a concentration of approximately
x 106cellsml`'.
Cellpreparationforflow cytometry
Suspensions of FNAs or solid tumour were permeabilised by
mixing with an equal volume of a 1% solution of saponin
(BDH, Poole, Dorset, UK) in Isoton II (Coulter). Samples
(100p,) were aliquoted into six tubes (when possible).
Insufficient samples of FNAs resulted in fewer markers being
measured. Ranked in order of priority, tubes were prepared
as follows: tube 1, 5 I1 of mouse IgG2b-fluorescein isothio-
cyanate (FITC) (control, Coulter); tube 2, 10 1I of strep-
tavidin-phycoerythrin (SPE) (secondary control, Becton
Dickinson, Oxford, Oxfordshire, UK); tube 3, 2 p1 of FITC-
conjugated anti-cytokeratin (NCL 5D3) antibody (Novocas-
tra Laboratories, Newcastle upon Tyne, UK); tube 4, 2 l1 of
5D3-FITC antibody (Novocastra) plus 2 lI of biotinylated
anti-oestrogen receptor antibody (ER-1D5, DAKO A/S,
Glostrup, Denmark); tube 5, 2 ,l of 5D3-FITC (Novocastra)
plus 2 pLI of biotinylated anti-c-erbB-2 antibody (Novocastra);
and tube 6, 2 p1 of 5D3-FITC plus 2 p1l of biotinylated anti-
epithelial growth factor receptor antibody (EGFR, Novocas-
tra). All samples were incubated for 20 min at 4C and then
washed in Isoton II (Coulter) using a preprogrammed cell
wash cycle (Diasent cell washer, Ross Labs, Macclesfield,
Cheshire, UK). To those cells labelled with a biotinylated
antibody, 10 1 of streptavidin-PE (Becton Dickinson) was
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added, mixed well and incubated for 20 min at 4°C followed
by washing in Isoton II (Coulter) using a preprogrammed
cell wash cycle. Cell pellets were resuspended in 0.5 ml of
Isoton II (Coulter) before examination on a FACScan flow
cytometer (Becton Dickinson) using prestored settings.
Assessment ofploidy
To tube 3 (labelled with 5D3-FITC) propidium iodide and
RNAse A (in Isoton II) were added to produce final concen-
trations of 0.025 mg ml1' and 1 mg ml-' respectively. Ploidy
was assessed by flow cytometry using prestored settings utilis-
ing the doublet discriminatory module (DDM). Linearity of
the amplifier and FACScan settings were checked using
chicken red blood cells (Sigma). Instrument verification and
quality control were carried out using DNA QC particles
(Becton Dickinson) according to the manufacturer's instruc-
tions.
Antibody standardisation
Antibody standardisation was carred out using Quantum
Simply Cellular bead standards (QSC, Research Triangle
Park, NC, USA) as previously described (Brotherick et al.,
1994a). Regression curves were constructed for each of the
four antibodies used.
Data analysis
Data analysis was performed using Lysys II software (Becton
Dickinson). Cells (10000 events) were gated (RI) on a dot
plot of forward-scatter light (FSC) against side-scatter light
(SSC) to exclude cellular debris and red cell contamination
(RI contained the cells of interest and contained not fewer
than 7000 events). Median fluorescence values for SPE and
cytokeratin FITC were measured. A further gate was set on
the cytokeratin positive cell population (3% positive gate on
tube 2 control) of cells (R2) and the median fluorescence
value obtained for those cells in both gates (R1*R2). The
Rl*R2 gate excludes debris (including cytokeratin-positive
debris) and those whole cells which were cytokeratin
negative. This gate contained on average 5000 events. No
sample was considered if fewer than 1000 events were pres-
ent. Median fluorescence values were converted into binding
capacities using Quickcal, QSC calibration software with cor-
rection for non-specific binding.
Resuts
Fifty-three confirmed solid breast cancers and 33 FNA sam-
ples were collected from 66 patients. Of these, 20 paired
samples were suitable for study. Reduction in the numbers of
available samples was due to failure to sample during surgery
or lack of tissue/cells during pathological examination.
Cytokeratin staining
All samples were assessed for cytokeratin staining. The data
were examined as a percentage of positive cells and as
number of cytokeratin molecules per cell. For the 53 solid
cancer specimens the mean percentage ofcytokeratin-positive
cells was 64% (s.e.m. ± 3.49). Examination of the FNA
group showed a mean value of 43% (s.e.m. ± 6.03). Statis-
tical analysis by Student's t-test showed these to be
significantly different (P = 0.004) with higher proportions of
non-epithelial cells in the FNAs. Examination of the same
data in terms of the number of molecules of cytokeratin per
cell showed no significant difference (P = 0.88). FNA samples
showed a range of between 5 x 102 and 3 x 108 molecules per
cell (mean = 1 x 10', s.e.m. ± 9 x 106) while solid tumours
showed between 4 x103 and 2 x 0I molecules per cell
(mean = l x 107, s.e.m. ±4 x 106).
The cytokeratin data on paired samples only were then
examined. Using Student's paired t-test cytokeratin contentCo mrsond makers for FMA anmldBr* hmnces 9 ~~~~~~~~~I Broec etal
was observed for each of the paired samples. FNAs showed a
mean value of 55.12% (s.e.m. ± 7.42) and the solid tumours
66.53% (s.e.m. ± 5.37); the result was not significantly
different (P = 0.51). Examination of the number of molecules
of cytokeratin on paired data again was not significantly
different (P = 0.2) with FNAs showing a mean value of
2 x 107 (s.e.m. 1.6 x 107) molecules and the solid tumours
3 x 10 (s.e.m. 9 x 05).
Oestrogen receptor staining
ER was also measured on all solid and FNA samples. ER
levels were calculated in terms of number of molecules.
Examination of the tumour alone, without cytokeratin
gating, showed a mean value of 3815 (s.e.m. ± 715) molecules
of ER per cell compared with 5746 (s.e.m. ± 932) when
cytokeratin gating was performed (Figure la). A strong cor-
relation was observed between these data (P<0.00001,
r = 0.71). Figure lb illustrates the relationship between ER
levels on FNA samples with a mean value of 96 222
(s.e.m. ± 90 747) molecules with and 2360 (s.e.m. ± 1102)
molecules without application of a cytokeratin gate
(P = 0.0002. r' = 0.40). It was noted that the FNA expressing
the highest level of ER in the cytokeratin-gated population
significantly increased the mean value, which is somewhat
misleading. The median value for this population was 4804
molecules per cell.
Twenty paired samples of FNA and tumour were
examined for ER expression. In the absence of a cytokeratin
gate a slight correlation was observed (P = 0.06, r2= 0.18.
Figure lc). ER expression levels varied between 1 and 16 315
(mean 2741, s.e.m. ± 995) molecules for the tumours and
between 1 and 9203 (mean 1854, s.e.m. ± 530) molecules for
the FNAs. FNAs showed lower levels of ER expression than
the tumours. Cytokeratin gating these same samples showed
ER expression levels varying between 181 and 27 444 (mean
5726, s.e.m. ± 1321) molecules for the tumours and between
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1 and 27047 (mean 4252. s.e.m. ± 1412) molecules for the
FNAs. The cytokeratin gating has brought the mean ER
expression for both FNA and solid tumour closer together.
The gate clearly affects the distribution pattern of ER expres-
sion and a correlation (P = 0.005, r' = 0.40) was observed
(Figure ld).
c-erbB-2 staining
Thirteen paired samples of FNA and tumour were examined
for c-erbB-2 expression. In the absence of a cytokeratin gate
no correlation was observed (P = 0.2, r' = 0.10). Expression
of c-erbB-2 levels varied between 186 and 22 115 (mean 4726,
s.e.m. ± 1693) molecules for the tumour and between 305
and 12 021 (mean 3632, s.e.m. ± 909 molecules) for the FNA.
The results are summarised in Figure 2a and show no clear
distribution pattern. Indeed, the regression line is so bad as
to be meaningless; it has been left in merely to illustrate this
point. However, in Figure 2b we show that employment of a
cytokeratin gate clearly affects the distribution pattern of
c-erbB-2 expression and a slight correlation can be observed
(P = 0.05, r2 = 0.30). Expression of c-erbB-2 levels varied
between 252 and 32 037 (mean 5505, s.e.m. ± 2756) molecules
for the tumour and between 865 and 9084 (mean 4051,
s.e.m. ± 785) molecules for the FNA.
EGFR staining
Thirteen paired samples of FNA and tumour were examined
for EGFR expression. In the absence of a cytokeratin gate
no correlation was observed (P = 0.21, r' = 0.14). EGFR
expression levels varied between 209 and 15 428 (mean 2450,
s.e.m. ± 1126) molecules for the tumours and between 1 and
9956 (mean 1626, s.e.m. ± 757) molecules for the FNAs. The
results are summarised in Figure 3a. However, employment
of a cytokeratin gate, like that for c-erbB-2, clearly affects the
distribution pattern for EGFR expression and a correlation
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Figure I (a) The linear regression correlation for ER expression on 53 solid tumour specimens with and without the employment
of a cytokeratin gate. (b) The correlation for ER expression on 33 FNA specimens with and without the employment of a
cvtokeratin gate. (c) The lack of correlation between FNA and solid tumour expression of ER without the use of a cytokeratin
gate. (d) The effect of cytokeratin gating on these samples.
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Figure 2 (a) The lack of correlation between FNA and solid
tumour expression of c-erbB-2 without the use of a cytokeratin
gate. (b) The effect of cytokeratin gating on these samples.
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F re 3 (a) The lack of correlation between FNA and solid
tumour expression of EGFR without the use of a cytokeratin
gate. (b) The effect of cytokeratin gating on these samples.
was observed (P = 0.05, r = 0.3, Figure 3b). EGFR expres-
sion levels varied between 186 and 22 115 (mean 4726,
s.e.m. = 1693) molecules for the tumours and between 305
and 12 021 (mean 3632, s.e.m. ± 909) molecules for the
FNAs.
Examination ofploidjv
Examination of ploidy was carried out on all 20 paired
tumour/FNA samples. In all cases the ploidy of FNAs was
the same regardless of cytokeratin gating. Ploidy of the solid
tumour was constant except for one case in which
cytokeratin gating revealed an aneuploid phenotype (near
diploid) which was classed as diploid previous to gating.
However, comparison of FNAs and solid tumours showed
some marked differences (denoted by an asterisk in Table I).
Two cases of missed aneuploids in the FNA group were
clearly revealed; on both occasions the tumour sample was
aneuploid when the FNA was diploid.
Diaussion
This paper set out to ask the question 'Are fine-needle
aspirates representative of the tumour from which they were
taken?' Examination of FNA samples by flow cytometry is
influenced by several factors and several potential problems
occur.
The most immediate problem identified has been obtaining
enough cells to perform an adequate flow cytometnrc
analysis. This is reflected in the reduced numbers of paired
data compared with individual solid tumour numbers. The
same problem has been identified during cytological diag-
nosis (Brown et al., 1991) with a small proportion of samples
containing no epithelial cells. The use of multiple aspirates
has alleviated this problem to some extent but leads to two
Table I Effect of cytokeratin gating on ploidy assessment
FNA Solid tumour
Patient No. All cells CK- cells All cells CK-cells
1 Tetraploid Tetraploid Tetraploid Tetraploid
2 Diploid Diploid Diploid Diploid
3 Aneuploid Aneuploid Aneuploid Aneuploid
4 Aneuploid Aneuploid Aneuploid Aneuploid
5 Diploid Diploid Diploid Aneuploida
6 Diploid Diploid Diploid Diploid
7 Tetraploid Tetraploid Tetraploid Tetraploid
8 Diploid Diploid Aneuploida Aneuploida
9 Diploid Diploid Diploid Diploid
10 Diploid Diploid Aneuploida Aneuploida
11 Tetraploid Tetraploid Tetraploid Tetraploid
12 Diploid Diploid Diploid Diploid
13 Diploid Diploid Diploid Diploid
14 Diploid Diploid Diploid Diploid
15 Diploid Diploid Diploid Diploid
16 Diploid Diploid Diploid Diploid
17 Diploid Diploid Diploid Diploid
18 Diploid Diploid Diploid Diploid
19 Aneuploid Aneuploid Aneuploid Aneuploid
20 Aneuploid Aneuploid Aneuploid Aneuploid
aDenotes the presence of missed aneuploid peaks.
further problems. Increased numbers of cells do not neces-
sarily mean that tumour cells are present. Cytological obser-
vation is still recommended at this stage to determine if all
epithelial cells are normal.
Furthermore, increased sampling leads to increased levels
of contaminating cells. Red cell contamination is combated
by the use of saponin, which causes leakage of haemoglobin
and loss of red cell side-scatter signal. The remaining cells
can be further 'purified' by use of cytokeratin gating to select
all epithelial cells.
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Cytokeratin levels have been measured on many tumours
(Angus et al., 1987; Ferrero et al., 1990; Brotherick et al.,
1994b) and have been shown to be of importance in gating
out debris and contaminating stromal and lymphoid cells
(Ferrero et al., 1990; Brotherick et al.. 1995). Such studies
have relied on high proportions of tumour cells being pres-
ent. However, cytokeratin also labels benign epithelial cells.
In this study we have shown cytokeratin levels for FNAs and
solid tumour samples are correlated when the number of
molecules are compared. Interestingly, however, analysis of
the percentage of positive cells showed a significant difference
between FNAs and solid samples. Whether this is a good
reason for abandoning the percentage of positive in favour of
number of molecules is not clear. Observations of true paired
data showed no difference between aspirate and tumour sam-
ple for percentage of positive or number of molecules of
cytokeratin.
Cytokeratin levels are usually high in solid samples of
breast tumours. Such a well-expressed marker would be
expected to occur at a detectable level in FNA samples.
resulting in a correlation between FNAs and solid tumours.
However, in the cases of ER and c-erbB-2. where
methodological constraints can result in poor marker detec-
tion. contaminating signals are likely to cause spurious
results. We have shown this to be true in the case of ER
expression (Brotherick et al.. 1995). in that non-epithelial
cells which are oestrogen receptor negative cause a reduction
in overall fluorescence with subsequent difficulty in determin-
ing the two populations from a fluorescence histogram. Low
cell numbers in FNA samples cause little correlation between
FNA and tumour (Figures lc. 2b and 3b). especially when no
cytokeratin gate is present. Cytokeratin gating may reduce
the number of cells measured but enhances the correlation
between tumour and FNA sample. The problem may
therefore be due not to low cell numbers but rather to the
effect that non-epithelial cells have on the fluorescence sig-
nal.
For this reason ER. EGFR and c-erbB-2 were examined
with and without cytokeratin gating. ER has already been
reported to be poorly expressed in breast tumours and
cytokeratin gating has been shown to be of importance in
measunng ER expression in solid tumours (Brotherick et al..
1995). The level of EGFR on both breast and bladder cells is
usually of the order of 1 x 104 molecules per cell (Brockhof
et al.. 1994; Brotherick et al.. 1994a). Expression of c-erbB-2
has been measured by flow cytometry (StAl et al.. 1994).
However c-erbB-2 expression, in terms of number of
molecules. has not been reported. although from our work
we have shown that around 3200 molecules per cell appears
to be the threshold above which positive cancers are deter-
mined (Brotherick et al.. 1994b).
On examining the total tumour population alone. with and
without cytokeratin gating, a good correlation for ER expres-
sion was found. Similarly, on the same aspirate a close
correlation for ER expression with or without cytokeratin
gating was seen. This reflects the reproducibility of the
analysis performed. However. when paired samples were
analysed we found that cytokeratin gating was important for
the FNA to be representative of the solid tumour. This
finding is reflected in Figures Ic and d. EGFR and c-erbB-2
expression both followed this pattern (Figures 2 and 3). with
no observable correlation for either. unless a cytokeratin gate
was used. These findings indicate that FNA sampling is only
representative of the solid tumour if a cytokeratin gate is
used.
Examination of ploidy has shown that aspirate and solid
tumour findings generally agree. In most cases abnormal
DNA histograms were clearly identifiable and cytokeratin
gating merely clarifies such peaks and also aids in the
measurement of cell cycle phases. However. two FNA sam-
ples failed to show the presence of an aneuploid population
of cells which was picked up dunrng examination of the solid
tumour even without the use of a cytokeratin gate. This
finding reflects the limitation in cell numbers to give a
reasonable DNA profile which can be easily analysed. The
aneuploid populations were clearly vlisualised with the aid of
cytokeratin gating. Alteration in ploid) as a result of regional
intratumoral variation was not considered to be a problem
because of the rigorous protocol for aspiration. It is
reasonable to conclude that DNA profiles need more cells to
allow analysis of small aneuploid populations. Solid tumour
samples have ample aneuploid cells Within the total cell
population and small aneuploid populations are relatively
easy to identify. The presence of cytokeratin-positive normal
epithelial cells can further hinder aneuploid detection. High
levels of cvtokeratin expression in FNA can mask the
presence of aneuploid populations. After gating one tumour
(which has been identified as diploid without cytokeratin
gating) it was correctly identified as aneuploid. In this case
cytokeratin gating was useful in identifying the abnormal
cells. These findings fit in with those of Ferrero et al. (1990).
who have assessed the use of cytokeratin staining in the
assessment of DNA content.
Use of FNA samples of breast cancers. while presenting
some problems. does not appear to be representative of the
underlying solid tumour. Despite the lower levels of detection
of ER. EGFR and c-erbB-2. these problems are surmoun-
table by the use of regulated cut-off points above which
positivity of a tumour is determined. Such levels would need
to be assessed in a large prospective study before they could
be applied to clinical samples. The methodology would allow
rapid detection of markers on breast tumours as near to the
time of clinical presentation and cytological diagnosis as
possible.
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